PRIMARY SURGERY VERSUS CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III-IV ORAL SQUAMOUS CELL CARCINOMA

Kravets O.V.; Protsyk V.S.; Burtyn O.V.; Khlynin O.V.; Gurianov V.G

Article

World of Medicine and Biology / №3(69), 2019 / PRIMARY SURGERY VERSUS CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III-IV ORAL SQUAMOUS CELL CARCINOMA

Kravets O.V., Protsyk V.S., Burtyn O.V., Khlynin O.V., Gurianov V.G

PRIMARY SURGERY VERSUS CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III-IV ORAL SQUAMOUS CELL CARCINOMA

About the author:	Kravets O.V., Protsyk V.S., Burtyn O.V., Khlynin O.V., Gurianov V.G
Heading	CLINICAL MEDICINE
Type of article	Scentific article
Annotation	The paper offers a comparative analysis of the treatment outcomes in patients with stages III-IV resectable oral squamous cell carcinoma. The overall and disease-free five-year survival rates in individuals who had undergone primary surgery with adjuvant radiotherapy (RT) chemoradiotherapy (CRT) were 55.4% and 59.6%, respectively, whereas in patients receiving definitive CRT, they were 18.9% and 15.2%. The comparison of the overall and disease-free survival curves revealed a statistically significant ((p <0.001) and (p <0.001)) higher overall and disease-free survival in patients undergoing primary surgery with adjuvant RT or CRT as compared with those having definitive CRT (HR = 0.32 (95% BI 0.25 - 0.41) and (HR = 0.23 (95% BI 0.18 - 0.30). The multivariable analysis showed that the prognosis of the overall and disease-free survival rates was statistically significantly affected by the primary tumour extent, cervical lymph node involvement and treatment modality.
Tags	oral squamous cell carcinoma, surgical treatment, radiotherapy, chemoradiotherapy
Bibliography	Rak v Ukraini, 2016–2017. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Bulletin of national cancer registry of Ukraine 2018; (19): 136. [in Ukrainian] Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, et al. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 2014 Feb; 25(2): 462-6. doi: 10.1093/annonc/mdt555 Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018 May; 16(5): 479-90. doi: 10.6004/jnccn.2018.0026. Crombie AK, Farah C, Tripcony L, Dickie G, Batstone M. Primary chemoradiotherapy for oral cavity squamous cell carcinoma. Oral Oncol. 2012 Oct; 48(10): 1014-18. doi: 10.1016/j.oraloncology.2012.03.027. D'Cruz AK, Vaish R, Dhar H. Oral cancer: Current status. Oral Oncol. 2018 Dec; 87: 64-9. doi: 10.1016/j.oraloncology.2018.10.013 Dixon L, Ramasamy S, Cardale K, Dyker K, Garcez K, Lee LW, et al. Long term patient reported swallowing function following chemoradiotherapy for oropharyngeal carcinoma. Radiother Oncol. 2018 Sep; 128(3): 452-8. doi: 10.1016/j.radonc.2018.06.014. Elbers JBW, Al-Mamgani A, Paping D, van den Brekel MWM, Jozwiak K, de Boer JP, et al. Definitive (chemo)radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma of the oral cavity. Oral Oncol. 2017 Dec; 75:163-168. doi: 10.1016/j.oraloncology.2017.11.006. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1; 31(7): 845-52. doi: 10.1200/JCO.2012.43.6097. Huang PW, Lin CY, Hsieh CH, Hsu CL, Fan KH, Huang SF, et al. A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. Biomed J. 2018 Apr; 41(2): 129-36. doi: 10.1016/j.bj.2018.04.003 Iyer NG, Tan DS, Tan VK, Wang W, Hwang J, Tan NC, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015 May 15; 121(10): 1599-607. doi: 10.1002/cncr.29251. Scher ED, Romesser PB, Chen C, Ho F, Wuu Y, Sherman EJ, et al. Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience. Oral Oncol. 2015 Jul; 51(7): 709-15. doi: 10.1016/j.oraloncology.2015.04.007. Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, et al. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1): 93-9. doi: 10.1002/lary.20716. Zhang H, Dziegielewski PT, Biron VL, Szudek J, Al-Qahatani KH, O'Connell DA, et al. Survival outcomes of patients with advanced oral cavity squamous cell carcinoma treated with multimodal therapy: a multi-institutional analysis. J Otolaryngol Head Neck Surg. 2013 Apr 19; 42: 30. doi: 10.1186/1916-0216-42-30. Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6): 744-51. doi: 10.1200/JCO.2012.43.8820.
Publication of the article	«World of Medicine and Biology» №3(69), 2019 year, 077-082 pages, index UDK 616.31-006.6-085.277.3-085.849.1
DOI	10.26724/2079-8334-2019-3-69-77-82